Plain-English translation of NCT06506643 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new cancer medication called KLS-1 that is given directly into your vein over several months. The trial has two main parts: first, researchers will test different doses of the medication to find the safest and most effective dose; then, they will give that chosen dose to more patients to confirm it works and is well-tolerated.
Researchers are developing this medication because current cancer treatments don't work for everyone or may cause serious side effects. This trial is a first step to see whether this new treatment could offer patients with solid tumors or blood cancers like chronic lymphocytic leukemia another option.
You likely qualify if…
You likely don't qualify if…
You will receive KLS-1 as an intravenous infusion every 3 weeks as part of treatment cycles. The first phase involves testing to find the right dose, which means you may receive a different dose than other participants; the second phase uses the dose found to be safest and most effective. Throughout the study, you will have regular blood tests, physical exams, and imaging scans to monitor how you are responding and check for side effects. Your participation will last several weeks to months, depending on which phase of the trial you join and how well the treatment works for you.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Ukraine